[2] Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology, 21(1), 169.https://doi.org/10.1186/s129...
[4] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial,Retrieved August 10, 2023 from https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301 [5...
利拉鲁肽是一款新型胰高血糖素样肽-1受体激动剂（ GLP⁃１ＲＡ），目前主要通过基因重组改造的酒酿...
[4] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial,Retrieved August 10, 2023 from https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301 [5...
12月15日,知名学术期刊《科学》公布胰高血糖素样肽-1(GLP-1)激动剂获选为2023年度科学突破(Science’s 2023 Breakthrough of the Year),这标志着在对抗肥胖症及其相关并发症的长期斗争中的重要里程碑。这项科学成就不仅在肥胖症治疗领域产生了深远影响,而且...
agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular ...
大量流行病学研究结果证实,超重和肥胖是诱发血脂异常、非酒精性脂肪肝 (Nonalcoholic fatty liver disease, NAFLD)、代谢综合征 (Metabolic syndrome ,MetS )、心血管疾病 (Cardiovascular disease,CVD)、2型糖尿病 (type 2 diabetes mellitus,T2DM)、慢性肾病、多囊卵巢综合征(Polycystic ovary syndrome,PCOS)、睡眠...
[4]Tucker ME. PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes. Medscape. March 27, 2019. Avaliable at: https://www.medscape.com/viewarticle/910986 Last assessed on 2019-04-08. [5]Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients wit...
题目:Pharmacogenetics of the Response to a GLP1R Agonist 摘要: Glucagon-like peptide 1 receptor (GLP1R) agonists are an important class of antidiabetic drugs with an attractive clinical profile – including improved glycemic...
However, two such trials have more recently and unexpectedly shown evidence of cardiovascular benefit with type 2 diabetes drugs, one of these being with another GLP-1 agonist, liraglutide (Victoza, Novo Nordisk), in theLEADERtrial, reported at last month's ADA meeting. ...